Search

Date 2016 Author/Creator Flaherty, Keith T

1. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Issue 10032 (14th May 2016)

Authors:
Haas, Naomi B; Manola, Judith; Uzzo, Robert G; Flaherty, Keith T; Wood, Christopher G; Kane, Christopher; Jewett, Michael; Dutcher, Janice P; Atkins, Michael B; Pins, Michael; Wilding, George; Cella, David; Wagner, Lynne; Matin, Surena; Kuzel, Timothy M; Sexton, Wade J; Wong, Yu-Ning; Choueiri, T...
Journal:
Lancet
Issue:
Volume 387:Issue 10032(2016)
Page Start:
2008
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Issue 12 (December 2016)

Authors:
Long, Georgina V; Grob, Jean-Jacques; Nathan, Paul; Ribas, Antoni; Robert, Caroline; Schadendorf, Dirk; Lane, Stephen R; Mak, Carmen; Legenne, Philippe; Flaherty, Keith T; Davies, Michael A
Journal:
Lancet oncology
Issue:
Volume 17:Issue 12(2016:Dec.)
Page Start:
1743
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search